Co-Led by DCVC Bio and Novo Holdings, Elo has raised a total of $45 million to date. New funding to expand Elo's pipeline of healthy, sustainable ingredients, and efforts to protect bananas and other staple crops from disease and climate change

在DCVC Bio和Novo Holdings的共同领导下，Elo迄今已筹集了4500万美元。新资金用于扩大Elo的健康、可持续成分管道，并努力保护香蕉和其他主要作物免受疾病和气候变化的影响

DURHAM, N.C., Jan. 24, 2024 /PRNewswire/ -- Elo Life Systems, the next-generation ingredient company reimagining the future of food, today announced its oversubscribed Series A2 financing round, raising $20.5 million.

北卡罗来纳州达勒姆，2024年1月24日/PRNewswire/--重塑食品未来的下一代配料公司Elo Life Systems今天宣布其A2系列融资轮超额认购，筹资2050万美元。

The round was jointly led by DCVC Bio and Novo Holdings. They are joined by Hanwha Next Generation Opportunity Fund, AccelR8, and Alexandria Venture Investments. Elo has raised a total of $45 million to date. This latest round of funding will help the company further scale and commercialize its sweetener product; increase its molecular-farming pipeline of healthy and sustainable ingredients; and expand its crop protection and productivity efforts, including work to save the banana from extinction..

本轮谈判由DCVC Bio和Novo Holdings联合牵头。Hanwha下一代机会基金、AccelR8和Alexandria Venture Investments也加入了他们的行列。迄今为止，Elo共筹集了4500万美元。这一最新一轮资金将有助于该公司进一步扩大其甜味剂产品的规模并将其商业化；增加其健康和可持续成分的分子农业管道；并扩大其作物保护和生产力工作，包括拯救香蕉免于灭绝的工作。。

'At Elo, we're on a mission to unlock nature's abilities to make consumers' favorite foods more delicious, healthy and planet friendly,' said Elo CEO Todd Rands. 'With strong support from our investors, we're well positioned to scale up our production and stay on track to launch our first product in 2026.'.

Elo首席执行官托德·兰兹（ToddRands）说：“在Elo，我们的使命是释放大自然的能力，使消费者喜爱的食物更加美味、健康和环保。”在投资者的大力支持下，我们有能力扩大生产规模，并有望在2026年推出第一款产品。”。

Through its molecular farming platform, Elo produces sought-after ingredients that are difficult to harvest from natural sources and cannot be synthesized through artificial or other techniques. The company uses easy-to-grow crops as biofactories for these ingredients, enabling local, commercial-scale production while reducing their cost and environmental footprint..

通过其分子农业平台，Elo生产出备受追捧的成分，这些成分很难从天然来源获得，也无法通过人工或其他技术合成。该公司使用易于种植的作物作为这些成分的生物工厂，实现了当地的商业规模生产，同时降低了成本和环境足迹。。

'Molecular farming will allow our food system to meet the needs of the world's growing population while reducing the resources needed to produce nutritious food,' said Stephen Van Helden, principal in the Bioindustrial Investments group at Novo Holdings US. 'Elo's approach – together with cutting edge science and an experienced management team – is aligned with Novo Holdings' purpose to deliver scaled solutions for better societal and planetary outcomes.'.

斯蒂芬·范·赫尔登（StephenVanHelden）说：“分子农业将使我们的粮食系统能够满足世界不断增长的人口的需求，同时减少生产营养食品所需的资源。”，Novo Holdings US生物工业投资集团的负责人。“Elo的方法-连同尖端科学和经验丰富的管理团队-与Novo Holdings的目标一致，即提供规模化的解决方案，以取得更好的社会和全球成果。”。

Elo's first molecular-farming product is the 'holy grail' of sweeteners – a natural, monk-fruit derived sweetener that is 300 times sweeter than sugar without calories. Launching in 2026, it can be used in thousands of food and beverage products to reduce sugar and artificial sweeteners while enhancing nutrition.

Elo的第一种分子农产品是甜味剂的“圣杯”——一种天然的僧侣果甜味剂，比不含卡路里的糖甜300倍。它于2026年推出，可用于数千种食品和饮料产品中，以减少糖和人造甜味剂，同时增强营养。

The company is also exploring the production of other ingredients, including novel proteins, natural preservatives, and high-value flavors and bio-actives..

该公司还在探索其他成分的生产，包括新型蛋白质、天然防腐剂、高价值香料和生物活性物质。。

'Elo's sweetener will be a major catalyst in the effort to lower sugar in our diets, improving human health and reducing the societal burden associated with chronic diseases,' said Kiersten Stead, managing partner, DCVC Bio. 'Meanwhile, their efforts to protect and improve the productivity of staple crops like the banana will have a meaningful impact on the food billions of people rely upon every day.'.

DCVC Bio管理合伙人基尔斯滕·斯特德（KierstenStead）说：“埃洛甜味剂将成为降低饮食中糖含量、改善人类健康和减轻与慢性病相关的社会负担的主要催化剂。”，他们保护和提高香蕉等主要作物生产力的努力将对数十亿人每天依赖的粮食产生重大影响。”。

In addition to molecular farming, Elo is working with major companies and NGOs to protect staple crops around the globe from the effects of disease and climate change. This includes a partnership with Dole in the creation of a fungal-resistant Cavendish banana to save the popular fruit from extinction.

除了分子农业，Elo还与大公司和非政府组织合作，保护全球主要作物免受疾病和气候变化的影响。这包括与多尔合作开发一种抗真菌的卡文迪什香蕉，以挽救这种受欢迎的水果免于灭绝。

Elo's banana proved successful in greenhouse testing and is currently undergoing field trials in Latin America..

Elo的香蕉在温室试验中取得了成功，目前正在拉丁美洲进行田间试验。。

About Elo Life SystemsElo is reimagining the future of food – focusing on ingredients that empower consumers to feel good about the food they eat every day. From unique plant-based sweeteners to saving crops like the banana from extinction, Elo harnesses the untapped potential of nature to make food tastier, healthier and resilient while requiring less from the planet.

关于Elo Life SystemsElo正在重新设想食品的未来-专注于使消费者对每天吃的食物感觉良好的成分。从独特的植物甜味剂到拯救香蕉等农作物免于灭绝，Elo利用大自然尚未开发的潜力，使食物更美味、更健康、更有弹性，同时减少对地球的需求。

To learn more, please visit www.elolife.com..

欲了解更多信息，请访问www.elolife.com。。

About DCVC BioDCVC Bio, based in San Francisco, backs companies building computationally advantaged or biologically transformative platforms with the potential to dramatically accelerate life science product development. DCVC Bio supports teams and science that treat diseases, provide nutrition to the planet, or produce sustainable alternatives to commonly used materials.

关于DCVC BioDCVC Bio总部位于旧金山，支持公司构建具有计算优势或生物变革性平台，有可能大大加速生命科学产品的开发。DCVC Bio支持治疗疾病、为地球提供营养或生产常用材料的可持续替代品的团队和科学。

Visit us at dcvc.com/bio, or follow us on LinkedIn or Twitter @DCVCBio..

访问我们 dcvc.com/bio， 或者在LinkedIn或Twitter@DCVCBio上关注我们。。

About Novo HoldingsNovo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation..

关于Novo HoldingsNovo Holdings是一家控股和投资公司，负责管理Novo Nordisk基金会的资产和财富。诺和诺德控股的目的是通过对诺和诺德基金会的资产产生有吸引力的长期回报，改善人们的健康以及社会和地球的可持续性。。

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio, with a long-term return perspective. Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

Novo Holdings是诺和诺德基金会（Novo Nordisk Foundation）的全资子公司，是诺和诺德股份有限公司（Novo Nordisk A/S）和诺维信股份有限公司（Novozymes A/S）的控股股东，管理着一个具有长期回报前景的投资组合。Novo Holdings是世界领先的生命科学投资者。Novo Holdings通过其种子、风险投资、成长和主要投资团队，在生命科学公司的各个发展阶段进行投资。

www.novoholdings.dk.

www.novoholdings.dk。

Media Contact:Sofia Spieler[email protected]

媒体联系人：索菲亚球员〔email protected〕

SOURCE Elo Life Systems

源Elo Life Systems